Key result
This paper is a protocol for a systematic review and meta-analysis comparing radiofrequency ablation and antiarrhythmic drugs for atrial fibrillation and does not report clinical results.
Why the study?
Data are limited regarding the potential benefit of different catheter ablation technologies versus antiarrhythmic drugs as an early rhythm control strategy for atrial fibrillation.
Does radiofrequency ablation reduce recurrence of atrial fibrillation and improve quality of life in participants with atrial fibrillation compared to antiarrhythmic drugs?
Systematic Review
Does radiofrequency ablation reduce recurrence of atrial fibrillation and improve quality of life in participants with atrial fibrillation compared to antiarrhythmic drugs?
This paper outlines a protocol for a systematic review and meta-analysis to evaluate the efficacy and safety of radiofrequency ablation versus antiarrhythmic drugs for atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Protocol alone yields no data; leaves open RFA versus AAD comparison in AF pending completed meta-analysis.
BACKGROUND: Antiarrhythmic drugs and radiofrequency ablation are first-line treatments of atrial fibrillation, however, there exists a paucity of data regarding the potential benefit of different catheter ablation technologies versus antiarrhythmic drugs as an early rhythm strategy. We performed a protocol for systematic review and meta-analysis to compare the efficacy and safety of radiofrequency ablation and antiarrhythmic drugs for the treatment of atrial fibrillation. METHODS: This review protocol is registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD42022375095). Additionally, this review will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols 2015 Statement. A computerized literature search will be performed in the following electronic databases from their inceptions to November 2022: PubMed, EMBASE, MEDLINE, Cochrane Central Register of Controlled Clinical Trials, China Knowledge Resource Integrated Database, Wanfang Data Information, and Weipu Database for Chinese Technical Periodicals. The risk of bias will be assessed independently by 2 authors using the Cochrane tool of risk of bias. All statistical analyses will be conducted using the software program Review Manager version 5.3. RESULTS: The results of this systematic review will be published in a peer-reviewed journal. CONCLUSION: This study provides evidence of the comparison of radiofrequency ablation and antiarrhythmic drugs for the treatment of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2022) conducted a systematic review in Atrial fibrillation. Radiofrequency ablation vs. Antiarrhythmic drug therapy was evaluated on Recurrence of atrial fibrillation and quality of life. This paper is a protocol for a systematic review and meta-analysis comparing radiofrequency ablation and antiarrhythmic drugs for atrial fibrillation and does not report clinical results.
Synapse has enriched 10 related papers. Consider them for comparative context: